The loan, issued by Azenta Germany GmbH to the buyer, Thelema S.à r.l., was settled ahead of its scheduled maturity date. Along with the principal, the company collected all accrued interest and released the equity share pledge that had served as collateral for the deal. The divestiture of B Medical Systems, which officially closed on July 1, 2026, was a strategic move for the life sciences firm.
Dr. Martin D. Madaus, Interim President and CEO, noted that the repayment marks the definitive end of the B Medical Systems exit. By converting the vendor financing into immediate cash, the company has successfully retired the associated credit risk, a step leadership points to as a core component of its disciplined capital allocation strategy.
Comments (0)
No comments yet. Be the first!